Exciting Developments in siRNA Research by Argo Biopharma
SHANGHAI and BOSTON – Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a pioneer in the development of small interfering RNA (siRNA) therapeutics, has announced the presentation of promising Phase I data for its investigational therapy BW-20805. This significant event will take place at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
BW-20805 is designed to target prekallikrein (PKK), offering a novel approach to treat hereditary angioedema (HAE). This therapy has the potential to prevent HAE attacks, a condition characterized by unpredictable swelling, which can be life-threatening when it affects the throat.
Insights from Phase I Clinical Data
The poster presentation titled "Hereditary Angioedema Prophylaxis With Prekallikrein siRNA-Phase 1 Safety Outcomes And Prekallikrein Levels" reflects the promising results of BW-20805. These findings demonstrate that the drug was well tolerated across various dose levels, with no increase in treatment-emergent adverse events noted.
Among the key highlights from the study:
Safety and Efficacy Findings
1. BW-20805 showed favorable tolerance across doses ranging from 50 to 600 mg.
2. There were no reported deaths or serious adverse events linked to the treatment.
3. Remarkably, the therapy produced mean maximum reductions in plasma PKK levels of approximately 75% at 50 mg and reaching up to 95% at 600 mg.
4. The suppression of PKK levels was sustained for up to 24 weeks, indicating the potential for less frequent dosing.
5. Reductions in additional pharmacodynamic markers support the drug's efficacy, reinforcing its therapeutic effects.
Company Leadership Remarks
Dr. Dongxu Shu, co-founder and CEO of Argo Biopharma, expressed enthusiasm regarding the findings, emphasizing the therapy's tolerance and effectiveness in lowering PKK levels. He indicated that advancing BW-20805 could significantly benefit individuals living with HAE.
Understanding Hereditary Angioedema
HAE is a rare genetic condition affecting a small population, with approximately 1.5 individuals per 100,000 suffering from this disorder globally. The unpredictable swelling associated with HAE can lead to critical situations, especially when it impacts the airway.
Current treatments often require frequent administration, making it essential to develop novel therapies that offer long-lasting protection against episodes. The innovative approach of BW-20805 in targeting human hepatic PKK mRNA presents a breakthrough opportunity for effective prevention methods.
About Argo Biopharma's Mission
Argo Biopharma is dedicated to creating advanced RNA interference (RNAi) therapeutics aimed at improving patient treatment options globally. With a broad and diverse pipeline of candidates, the company focuses on various medical indications, including cardiovascular diseases, viral infections, metabolic disorders, and conditions affecting rare populations. Presently, Argo Biopharma has six RNAi candidates in various stages of clinical trials.
For more details on Argo Biopharma's groundbreaking work, visit the official website.
Frequently Asked Questions
What is BW-20805?
BW-20805 is an investigational siRNA therapy targeting prekallikrein (PKK) designed to prevent attacks related to hereditary angioedema.
How did Argo Biopharma report on BW-20805's safety?
The Phase I data indicated that BW-20805 was well tolerated across all dose levels with no serious adverse effects reported.
What are the potential benefits of BW-20805?
The therapy may provide sustained reductions in PKK levels, indicating the possibility of long-lasting prevention from hereditary angioedema attacks.
What is hereditary angioedema (HAE)?
HAE is a rare genetic disorder characterized by sudden swelling, which can become life-threatening when it affects the throat.
How many RNAi candidates is Argo Biopharma developing?
Argo Biopharma currently has six RNAi candidates in clinical development targeting various medical conditions.
